Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non -small -cell lung cancer (OAK): a phase 3, open -label, multicentre randomi sed controlled trial. Lancet.